Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment

Next Previous
Trial Profile

An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Study 2
  • Sponsors Roche

Most Recent Events

  • 08 Nov 2019 Results (n=187) of exploratory analysis using pooled data from two clinical studies (NP28673 and NP28761) were published in the Journal of Thoracic Oncology
  • 05 Jun 2018 Results (n=207) of an exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer patients using final pooled phase II OS and safety data (NCT01801111 and NCT01871805), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
  • 05 Jun 2018 Results of a pooled analysis of NP28673 and NP28761 trials (n=225) assessing the survival and safety, presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top